Latanoprost |
Xalatan |
Article: Latanoprost
![]() | |
| Latanoprost | |
| Systematic (IUPAC) name | |
| propan-2-yl 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pentyl) -cyclopentyl] hept-5-enoate | |
| Identifiers | |
| CAS number | 130209-82-4 |
| ATC code | S01EE01 |
| PubChem | 60798 |
| DrugBank | APRD01065 |
| Chemical data | |
| Formula | C26H40O5 |
| Mol. weight | 432.593 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 17 minutes |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. | ? |
| Legal status | |
| Routes | ? |
Latanoprost (pronounced la-TA-noe-prost) ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes. It is also known by the brand name of Xalatan Op manufactured by Pfizer.
Molecular formula: C26H40O5
Possible side effects:
- May cause blurred vision;
- May cause eyelid redness;
- May permanently darken eyelashes;
- May cause eye discomfort;
- May eventually cause permanent darkening of the iris to brown (heterochromia);
- May cause a temporary burning sensation during use.
- May cause thickening of the eyelashes.
Resources
- Latanoprost (Drug Digest)
- Xalatan (Drug Digest)

Not Signed In - 

